Ticagrelor
Brilinta
- Dosage form
- Tablet
- Available strengths
- 60 mg, 90 mg
- Drug class
- Platelet aggregation inhibitor (P2Y12 receptor antagonist)
- Common brand
- Brilinta
Clinical overview. Ticagrelor (brand name Brilinta) is an antiplatelet medication that, combined with low-dose aspirin, helps prevent heart attack, stroke, and cardiovascular death in patients with acute coronary syndrome or a history of heart attack or coronary artery disease with diabetes. It works by blocking the P2Y12 receptor on platelets to reduce blood clotting. The most significant risk is increased bleeding, and the drug should not be stopped abruptly without medical advice because doing so raises cardiovascular risk.
Indication
Common therapeutic uses
- Ticagrelor, combined with low-dose aspirin, is used to reduce the risk of further heart attack, stroke, or cardiovascular death in patients who have had acute coronary syndrome.
- Ticagrelor, combined with low-dose aspirin, is used for long-term secondary prevention in patients with a history of heart attack at least one year earlier who remain at high risk.
- Ticagrelor, combined with low-dose aspirin, is used to reduce the risk of a first heart attack or stroke in patients with coronary artery disease, type 2 diabetes, and a history of a coronary artery procedure (percutaneous coronary intervention).
Pregnancy
Risk assessment and monitoring considerations
- The safety of ticagrelor during pregnancy has not been established, since no clinical studies have been conducted in pregnant women.
- Women who can become pregnant should use appropriate contraception while taking ticagrelor.
Breastfeeding
Infant exposure considerations
- It is not known whether ticagrelor passes into human breast milk, though studies in rats have shown that ticagrelor and its active metabolites are excreted into milk.
- Breastfeeding is not recommended while taking ticagrelor.
Geriatrics
Dosing and tolerability considerations
- No overall differences in safety or effectiveness were seen between older and younger patients in large clinical trials.
- No dose adjustment is required based on age alone.
Pediatrics
Use in children and adolescents
- The safety and effectiveness of ticagrelor in patients under 18 years of age have not been established, and Health Canada has not authorized a pediatric indication.
- In a study of children with sickle cell disease, ticagrelor did not reduce painful crisis episodes, and it should not be used for this condition.
Dosage & Administration
Practical dosing and administration
- For acute coronary syndrome, treatment starts with a single 180 mg loading dose, then continues at 90 mg twice daily.
- For long-term secondary prevention after a heart attack at least one year earlier, the dose is 60 mg twice daily, with no loading dose required.
- For coronary artery disease with type 2 diabetes and a history of percutaneous coronary intervention, the dose is 60 mg twice daily, with no loading dose required.
- Ticagrelor is always taken together with a daily low dose of aspirin (75 to 150 mg), unless aspirin is specifically not suitable.
- Doses of aspirin above 150 mg daily are not recommended with ticagrelor, since higher aspirin doses may reduce ticagrelor's relative benefit.
- No dose adjustment is required for kidney impairment or for older adults.
- Ticagrelor is not recommended in patients with moderate or severe liver impairment.
- Patients who cannot swallow tablets whole may have the tablet crushed and mixed with water, or given through a feeding tube.
- If a dose is missed, the next dose should be taken at its regularly scheduled time; the missed dose should not be doubled up.
Overdose
Recognizing and responding to overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- There is no known antidote to reverse the effects of ticagrelor, and it cannot be removed by dialysis.
- The main risk of overdose is a prolonged increased risk of bleeding due to excessive platelet inhibition.
- Ticagrelor has been well tolerated in single doses up to 900 mg, though at higher doses, stomach upset becomes the limiting effect.
- Other possible effects of overdose include shortness of breath and pauses in the heart's rhythm (ventricular pauses).
- If bleeding occurs after an overdose, appropriate supportive measures should be taken, and heart rhythm monitoring should be considered.
Common side effects
Frequently reported tolerability concerns
- Shortness of breath (dyspnea) may occur and is usually mild to moderate, often improving with continued treatment.
- Nosebleeds may occur.
- Bruising more easily may occur.
- Nausea or diarrhea may occur.
- Dizziness may occur.
- Headache may occur.
- Low-grade bleeding, such as after a minor cut or procedure, may occur.
Serious side effects
Findings that may require urgent assessment
Serious side effects require immediate discussion with the prescriber or emergency care.
- Ticagrelor increases the risk of bleeding, which can be serious or life-threatening, including bleeding inside the skull.
- Slow or irregular heartbeats (bradyarrhythmias), including heart block, have been reported, sometimes requiring temporary pacing.
- A rare but serious blood disorder called thrombotic thrombocytopenic purpura has been reported very rarely.
- Central sleep apnea, a breathing problem during sleep, has been reported.
- Uric acid levels can rise, which may trigger gout or, rarely, kidney problems related to uric acid buildup.
- Kidney function can be affected, with creatinine levels rising during treatment for reasons that are not fully understood.
- Stopping ticagrelor too early increases the risk of a heart attack or cardiovascular death related to the underlying heart disease.
- Seek urgent medical attention for signs of serious bleeding, such as vomiting blood, black or bloody stools, coughing up blood, or a severe headache with confusion or weakness.
Use with caution
Situations requiring closer assessment
- Use with caution in patients with a tendency to bleed, such as from recent trauma, recent surgery, a clotting disorder, or recent gastrointestinal bleeding.
- Use with caution in patients at increased risk of trauma or falls.
- Use with caution in patients taking warfarin or other blood thinners, since combined use increases bleeding risk.
- Use with caution in patients taking nonsteroidal anti-inflammatory drugs (NSAIDs), which can add to bleeding risk.
- Use with caution in patients at risk for slow heart rhythms, including those with a history of bradyarrhythmia.
- Use with caution in patients with a history of gout or high uric acid levels.
- If elective surgery is planned and antiplatelet effect is not wanted, ticagrelor should be stopped about 5 days beforehand.
- Do not stop ticagrelor early without discussing it with your doctor, since premature discontinuation increases cardiovascular risk.
Contraindications
Situations where therapy may be inappropriate
- Contraindicated in patients with known hypersensitivity to ticagrelor or any ingredient in the formulation.
- Contraindicated in patients with active pathological bleeding, such as a peptic ulcer.
- Contraindicated in patients with a history of bleeding inside the skull (intracranial hemorrhage).
- Contraindicated in patients with moderate to severe liver impairment.
- Contraindicated with strong CYP3A4 inhibitor drugs, such as ketoconazole, clarithromycin, and ritonavir, because they can greatly increase ticagrelor blood levels.
Drug interactions
Clinically relevant combinations
- Strong CYP3A4 inhibitors, such as ketoconazole and clarithromycin, significantly raise ticagrelor blood levels and are contraindicated.
- Strong CYP3A4 inducers, such as rifampin, phenytoin, and carbamazepine, can significantly lower ticagrelor blood levels and reduce its effectiveness; alternative treatments should be considered.
- Simvastatin and lovastatin doses above 40 mg should be avoided with ticagrelor, since ticagrelor raises their blood levels and the risk of muscle toxicity.
- Rosuvastatin doses above 20 mg should be avoided with ticagrelor for the same reason.
- Digoxin blood levels can rise when combined with ticagrelor, so monitoring is recommended.
- Warfarin combined with ticagrelor increases bleeding risk, and the combination should be used with caution.
- Morphine and other opioids can delay and reduce the absorption of ticagrelor by slowing stomach emptying.
- Ticagrelor does not appear to reduce the effectiveness of hormonal contraceptives.
Food interactions
Meal-related administration
- Ticagrelor can be taken with or without food; a high-fat meal does not meaningfully change how much of the drug reaches the bloodstream.
Time of administration
Practical scheduling
- Ticagrelor is taken twice daily, approximately 12 hours apart, with or without food.
Storage
Product handling
- Store ticagrelor tablets between 2°C and 30°C.
Patient take-away
Key counselling points for a quick closing summary
- Ticagrelor is an antiplatelet medicine, always used together with low-dose aspirin, that helps prevent heart attack and stroke in people with heart disease.
- Take it exactly as prescribed and do not stop taking it early without talking to your doctor, since stopping suddenly raises your risk of a heart attack.
- This medicine increases your risk of bleeding, so tell every healthcare provider, including your dentist, that you are taking it.
- Report any unusual or severe bleeding, shortness of breath, or signs of an irregular or slow heartbeat right away.
- Avoid taking aspirin doses higher than what your doctor recommends while on this medicine.
References
Source material and product information
For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.